Indeed, in the last two decades, biological tumor analysis permitted to classify BC prognostic outcomes according to molecular classification: luminal (positive estrogen and/or progesterone receptors—ER/PgR), triple negative (negative ER/PgR/negative Her2), and Her2 overexpression phenotypes (positive Her2) (1, 2). Here, ESR1 is linked to neoplasm.